Bionomics Limited

102 articles with Bionomics Limited

• Quarterly Activities and Cashflow Report - Jan 30, 2023

  1/30/2023

  Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

• Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

  12/19/2022

  Bionomics Limited announced results from its Phase 2 randomised, double-blind, placebo-controlled, multi-centre, dose-ranging PREVAIL study to evaluate the safety, tolerability, and efficacy of BNC210 for the acute treatment of Social Anxiety Disorder.

• Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive OfficerExperienced biotech executive to lead the next phase of growth

  12/15/2022

  Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer, effective 5 January 2023.

• Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

  12/2/2022

  Bionomics Limited today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st Annual meeting of the American College of Neuropsychopharmacology (ACNP) to be held in-person Sunday through Wednesday, December 4-7, 2022 in Phoenix, Arizona.

• Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

  11/16/2022

  Bionomics Limited announced the pricing of an underwritten follow-on offering in the United States of 641,026 American Depositary Shares, each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS.

• Bionomics Limited to Participate in Upcoming November 2022 Investor Conferences

  11/2/2022

  Bionomics Limited announced that it will participate in the following upcoming investor conferences in November.

• Quarterly Activities Report for September 2022

  10/25/2022

  Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

• Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

  10/18/2022

  Bionomics Limited is pleased to announce that the Company has received A$4,634,307.30 research and development tax incentive refund relating to the financial year ended June 2022.

• Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

  10/4/2022

  Bionomics Limited announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.

• Bionomics to Host KOL Webinar on BNC210 and Social Anxiety DisorderBNC210 is a First-in-Class Candidate in Clinical Development for the Acute Treatment of Social Anxiety Disorder with FDA Fast Track Designation

  9/21/2022

  Bionomics Limited today announced that it will host a Key Opinion Leader (KOL) webinar on BNC210, a proprietary, first-in-class oral therapeutic with potential to treat Social Anxiety Disorder (SAD) on Wednesday, October 12, 2022 at 2:30pm – 3:30pm ET.

• Bionomics to Participate in Upcoming September 2022 Investor Conferences

  8/31/2022

  Bionomics Limited announced that it will participate in the following upcoming investor conferences in September.

• Bionomics reports Full Year Financial Results - Aug 25, 2022

  8/25/2022

  Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need.

• 

  Global Roundup: Connect in Pharma, CanSino Biologics, HUTCHMED and More

  8/11/2022

  The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.

• Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

  8/8/2022

  Bionomics Limited, a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development tax incentive refund relating to the financial year ended June 2021.

• Quarterly Activities Report for June 2022

  7/29/2022

  Bionomics Limited, a global, clinical stage biopharmaceutical company, released its Quarterly Activities and ASX Appendix 4C Cashflow Reports.

• Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

  7/8/2022

  Bionomics Limited announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a panel on “Unmet Needs and Novel Therapies in Neuropsychiatry” at the William Blair Biotech Focus Conference taking place virtually and in-person in New York on July 12-13, 2022.

• Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

  6/27/2022

  Bionomics Limited announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a fireside chat at the First Annual H.C. Wainwright Mental Health Conference taking place virtually and in-person in New York on June 27, 2022.

• Bionomics Investor Webinar - June 13, 2022

  6/13/2022

  Bionomics Limited invites shareholders and interested parties to attend an investor webinar with Executive Chairman Dr. Errol De Souza and Vice President of Strategy and Corporate Development Mr. Connor Bernstein, at 10.30am on Wednesday 15 June 2022 on Tuesday 14 June 2022).

• Bionomics Limited to Participate in Upcoming Investor Conferences - May 16, 2022

  5/16/2022

  Bionomics Limited announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

• Bionomics' Half-Year Report - Feb 24, 2022

  2/24/2022

  Bionomics Limited, announced its half-year report for the half-year ended 31 December 2021.